Affluent Medical SAS

Chart & Performance

D1W1MN

No data to show

P/E

—

P/S

45.80

EPS

—

Div Yield, %

—

Shrs. gr., 5y

19.02%

Rev. gr., 5y

95.37%

Revenues

-8.59%

Net income

-16m

L+2.80%

CFO

-12m

L+8.78%

Profile

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

URL

https://www.affluentmedical.com/

IPO date

Jun 14, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2017‑12	2016‑12
Income
Revenues	1,224 -8.59%	1,339 -7.72%
Cost of revenue	14,290	7,738
Unusual Expense (Income)
NOPBT	(13,066)	(6,399)
NOPBT Margin
Operating Taxes	(1,357)	(173)
Tax Rate
NOPAT	(11,709)	(6,226)
Net income	(15,653) 2.80%	(15,227) 2.75%
Dividends
Dividend yield
Proceeds from repurchase of equity	12,553	5,742
BB yield	-23.32%	-18.10%
Debt
Debt current	2,077	2,062
Long-term debt	16,036	16,760
Deferred revenue
Other long-term liabilities	114	112
Net debt	16,437	16,181
Cash flow
Cash from operating activities	(12,054)	(11,081)
CAPEX	(171)	(146)
Cash from investing activities	(184)	(146)
Cash from financing activities	11,316	2,401
FCF	(11,114)	(5,975)
Balance
Cash	1,658	2,580
Long term investments	18	61
Excess cash	1,615	2,574
Stockholders' equity	(54,580)	(49,884)
Invested Capital	103,300	98,488
ROIC
ROCE
EV
Common stock shares outstanding	29,092	18,887
Price	1.85 10.12%	1.68 -70.47%
Market cap	53,820 69.62%	31,729 -70.01%
EV	70,257	118,500
EBITDA	(10,653)	(4,051)
EV/EBITDA
Interest	393	1,080
Interest/NOPBT